Board approves half-year results and 5% interim dividend
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.2 pts more than Nifty Microcap 250 and 4.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
On October 23, 2026, the board approved the company’s unaudited financial results and cash flow statements for the half year ended September 30, 2026. The results were reviewed by the Audit Committee and received a limited review report from statutory auditors SKLR & Co. LLP. The board declared an interim dividend of Rs 0.50 per share, equal to 5% of the Rs 10 face value, payable within 30 days. October 30, 2026 is the record date.
Eligible shareholders may receive Rs 0.50 per share. The notice does not provide the financial figures, so the result-related stock impact cannot be assessed.